Etoricoxib Strides
Generic Selective COX-2 Inhibitor for Osteoarthritis Pain
Etoricoxib Strides is a generic medicine containing etoricoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor belonging to the coxib class of nonsteroidal anti-inflammatory drugs (NSAIDs). Available as a 30 mg film-coated tablet, it is used primarily for the symptomatic treatment of osteoarthritis in adults aged 16 years and older. Etoricoxib works by selectively blocking the COX-2 enzyme involved in inflammation while largely sparing COX-1, which helps protect the stomach lining. This selectivity may offer a lower risk of gastrointestinal side effects compared to traditional NSAIDs such as ibuprofen or naproxen. Etoricoxib Strides requires a prescription, is taken once daily, and is bioequivalent to the original branded etoricoxib product (Arcoxia). It is not approved for use in the United States but is available in European and other international markets.
Quick Facts
Key Takeaways
- Etoricoxib Strides is a generic etoricoxib product available as a 30 mg film-coated tablet, bioequivalent to the original branded product Arcoxia, and used primarily for the symptomatic treatment of osteoarthritis.
- As a selective COX-2 inhibitor, etoricoxib reduces pain, inflammation, and swelling by targeting the COX-2 enzyme while sparing COX-1, potentially reducing gastrointestinal side effects compared to traditional NSAIDs like ibuprofen or diclofenac.
- Etoricoxib has a long half-life of approximately 22 hours, allowing convenient once-daily dosing. At the 30 mg dose, it provides effective relief of osteoarthritis symptoms with a favorable tolerability profile.
- It is contraindicated in patients with established cardiovascular disease, uncontrolled hypertension, severe liver or kidney disease, inflammatory bowel disease, pregnancy, and breastfeeding.
- The most common side effect is stomach pain; serious but less common risks include cardiovascular events, elevated blood pressure, and liver problems. Regular medical monitoring is recommended during treatment.
What Is Etoricoxib Strides and What Is It Used For?
Etoricoxib Strides belongs to the coxib subclass of nonsteroidal anti-inflammatory drugs (NSAIDs), a group of medicines designed to selectively inhibit cyclo-oxygenase-2 (COX-2). The COX-2 enzyme is primarily responsible for producing prostaglandins at sites of tissue damage and inflammation. By selectively blocking COX-2, etoricoxib reduces prostaglandin synthesis in inflamed tissues, thereby providing effective pain relief, reducing swelling, and lowering fever, while having a significantly lesser effect on COX-1—the enzyme that helps protect the stomach lining and supports normal platelet function.
Etoricoxib Strides is manufactured by Strides Pharma, one of the world’s leading generic pharmaceutical companies headquartered in Bangalore, India, with manufacturing facilities spanning multiple countries. As a generic medicine, Etoricoxib Strides must demonstrate bioequivalence to the original branded product, meaning it delivers the same amount of active ingredient (etoricoxib) at the same rate and to the same extent as the reference medicine. Generic etoricoxib products undergo rigorous regulatory assessment by the European Medicines Agency (EMA) or national competent authorities before they receive marketing authorization.
Etoricoxib was originally developed by Merck & Co. and first received marketing authorization in 2002 under the brand name Arcoxia. Since patent expiry, several generic versions have become available, including Etoricoxib Strides. The active substance is now available in over 80 countries worldwide, including throughout Europe, Latin America, and Asia-Pacific. Notably, etoricoxib has not received FDA approval for the United States market; the FDA declined approval in 2007, requesting additional cardiovascular safety data. Nevertheless, it remains one of the most widely prescribed selective COX-2 inhibitors globally, with extensive clinical trial data supporting its efficacy and safety profile.
Approved Indications for the 30 mg Strength
Etoricoxib Strides is available exclusively as a 30 mg film-coated tablet. At this dose, it is indicated for the following condition in patients aged 16 years and older:
- Osteoarthritis – The most common form of arthritis, caused by gradual breakdown of the cartilage that cushions the ends of bones in joints. This leads to pain, stiffness, swelling, and reduced joint mobility, particularly in weight-bearing joints such as the knees, hips, and spine. Etoricoxib 30 mg is the recommended starting dose for osteoarthritis and effectively manages the chronic pain and inflammation associated with this condition. Clinical trials have demonstrated that etoricoxib 30 mg provides statistically significant and clinically meaningful improvement in pain and physical function compared to placebo in patients with osteoarthritis.
If higher doses of etoricoxib are required (for example, 60 mg for osteoarthritis if 30 mg provides insufficient relief, or 60–120 mg for other indications such as rheumatoid arthritis, ankylosing spondylitis, or acute gout), your doctor may prescribe a different etoricoxib product available in the appropriate strength. Etoricoxib Strides is available only in the 30 mg strength.
How Etoricoxib Works
Etoricoxib exerts its therapeutic effects through highly selective inhibition of the COX-2 enzyme. In human whole blood assays, etoricoxib demonstrates a COX-1 to COX-2 selectivity ratio of approximately 106-fold, making it one of the most COX-2 selective agents in clinical use. This high selectivity means that at therapeutic doses, etoricoxib produces potent anti-inflammatory and analgesic effects through COX-2 inhibition while having minimal impact on COX-1-mediated physiological processes such as gastric mucosal protection, platelet aggregation, and renal hemodynamics.
After oral administration, etoricoxib is rapidly and almost completely absorbed, with an oral bioavailability of approximately 100%. Peak plasma concentrations are typically reached within 1 hour, and its elimination half-life of approximately 22 hours supports once-daily dosing. The drug is extensively metabolized in the liver, primarily by CYP3A4 enzymes, and approximately 70% of an oral dose is excreted in the urine as metabolites. Etoricoxib is highly protein-bound (approximately 92%) and has a volume of distribution of approximately 120 liters in humans.
The MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) program, one of the largest NSAID outcome studies ever conducted with over 34,700 patients, demonstrated that etoricoxib had a comparable cardiovascular safety profile to diclofenac while showing significantly fewer upper gastrointestinal events, including clinical upper GI events such as perforations, obstructions, and bleeding. This landmark study, published in The Lancet in 2007, has been central to the regulatory assessment of etoricoxib’s benefit-risk profile across all approved doses.
Generic Medicines: Quality and Bioequivalence
Etoricoxib Strides is a generic medicine, meaning it contains the same active substance as the original reference product (Arcoxia) and has been shown to be bioequivalent. Regulatory authorities require generic manufacturers to demonstrate that their product delivers the same amount of the active ingredient into the bloodstream at the same rate as the reference product. This is established through bioequivalence studies comparing the pharmacokinetic profiles of the generic and reference medicines in healthy volunteers. Generic medicines undergo the same rigorous quality standards for manufacturing, stability, and purity as originator products, ensuring that patients receive a medicine of equivalent quality and efficacy.
What Should You Know Before Taking Etoricoxib Strides?
Before starting treatment with Etoricoxib Strides, it is essential to carefully review the contraindications and precautions with your doctor. Etoricoxib, like all NSAIDs, carries certain risks that must be weighed against its benefits. Your doctor will consider your complete medical history, current medications, and individual risk factors before prescribing this medicine. Although the 30 mg dose is the lowest available strength and is generally well tolerated, the same general precautions that apply to all etoricoxib-containing medicines also apply to Etoricoxib Strides.
Contraindications
Etoricoxib Strides must not be taken in the following situations. If any of these apply to you, inform your doctor before starting treatment:
- Allergy to etoricoxib or any excipient – If you have experienced allergic reactions to etoricoxib or any other ingredient in the tablets.
- NSAID hypersensitivity – If you have had allergic reactions (including asthma, urticaria, rhinitis, or angioedema) after taking aspirin or any other NSAID, including other COX-2 inhibitors.
- Active peptic ulcer or gastrointestinal bleeding – If you currently have a stomach ulcer or bleeding in the stomach or intestines.
- Severe liver disease – Advanced hepatic impairment (Child-Pugh score above 9) significantly alters drug metabolism and increases the risk of toxicity.
- Severe kidney disease – Estimated creatinine clearance below 30 ml/min.
- Inflammatory bowel disease – Active Crohn’s disease, ulcerative colitis, or colitis.
- Uncontrolled hypertension – Blood pressure that has not been adequately controlled with treatment. If you are uncertain whether your blood pressure is under control, check with your doctor.
- Established cardiovascular disease – Including heart failure (moderate or severe), angina pectoris (chest pain), history of myocardial infarction, coronary artery bypass graft surgery, peripheral arterial disease, or any form of cerebrovascular disease (stroke or transient ischemic attack).
- Pregnancy and breastfeeding – Etoricoxib Strides must not be used during pregnancy or while breastfeeding.
- Age under 16 years – Not approved for use in children and adolescents below 16 years of age.
Warnings and Precautions
Even when Etoricoxib Strides is not strictly contraindicated, there are many situations in which extra caution is necessary. Speak to your doctor before using etoricoxib if any of the following apply:
Selective COX-2 inhibitors may be associated with a small increased risk of cardiovascular thrombotic events, including myocardial infarction and stroke, particularly when used at high doses for prolonged periods. Use the lowest effective dose for the shortest duration necessary. Etoricoxib Strides must not be used in patients with established cardiovascular disease or uncontrolled hypertension.
- History of gastrointestinal problems – Previous stomach or duodenal ulcers, gastrointestinal bleeding, or peptic ulcer disease increase the risk of recurrence. The 30 mg dose carries a lower GI risk than higher doses, but vigilance is still required.
- Dehydration – If you are dehydrated (for example, after prolonged vomiting or diarrhea), rehydration is recommended before starting etoricoxib.
- Fluid retention or edema – Etoricoxib may cause sodium and fluid retention, which can worsen pre-existing edema or heart failure.
- History of heart failure or cardiac disease – Even without established cardiovascular disease, discuss your cardiac history with your doctor.
- Hypertension – Etoricoxib can increase blood pressure in some patients, even at the 30 mg dose. Your doctor should monitor your blood pressure regularly during treatment, particularly within the first two weeks.
- Liver or kidney disease – Even mild to moderate impairment requires careful monitoring. Patients with moderate liver disease (Child-Pugh score 7–9) should not exceed 30 mg daily (which is the only available strength of Etoricoxib Strides).
- Infections – Etoricoxib may mask fever and other signs of infection, potentially delaying appropriate treatment.
- Cardiovascular risk factors – Diabetes mellitus, high cholesterol, or smoking increase your baseline risk for cardiovascular events.
- Elderly patients (over 65 years) – Etoricoxib works equally well in older adults, but physicians should monitor treatment more closely due to the increased vulnerability to adverse effects in this population.
Pregnancy and Breastfeeding
Etoricoxib Strides is contraindicated during pregnancy. If you are pregnant, suspect you may be pregnant, or are planning to become pregnant, do not take this medicine. Discontinue Etoricoxib Strides immediately and consult your doctor if you become pregnant during treatment. NSAIDs, including selective COX-2 inhibitors, can have adverse effects on fetal development, particularly on the cardiovascular and renal systems, especially during the third trimester. All NSAIDs may inhibit prostaglandin synthesis and thereby potentially delay labor and prolong gestation.
It is not known whether etoricoxib passes into human breast milk. Studies in rats have shown that etoricoxib is excreted in breast milk. If you are breastfeeding or planning to breastfeed, consult your doctor before taking Etoricoxib Strides. If you do take this medicine, you should not breastfeed. Etoricoxib is also not recommended for women who are trying to conceive, as it may impair fertility by affecting ovulation. This effect is reversible upon discontinuation of the drug.
Driving and Using Machines
Dizziness and drowsiness have been reported by some patients taking etoricoxib. If you experience either of these effects, do not drive, operate machinery, or perform activities requiring alertness until the symptoms resolve. Always assess your own fitness before engaging in such activities when taking any medication.
Important Information About Excipients
Etoricoxib Strides tablets may contain lactose. If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medicine. Consult the patient information leaflet supplied with your specific pack for a complete list of excipients.
How Does Etoricoxib Strides Interact with Other Drugs?
Drug interactions are an important consideration when taking etoricoxib, even at the lower 30 mg dose. The metabolism of etoricoxib occurs primarily through CYP3A4 in the liver, and it can affect the pharmacokinetics and pharmacodynamics of several other medications. Conversely, drugs that strongly induce CYP3A4 (such as rifampicin) can reduce etoricoxib plasma concentrations. Always inform your doctor and pharmacist about all medications you are currently taking, including over-the-counter medicines, dietary supplements, and herbal remedies.
Major Interactions
| Drug / Drug Class | Interaction Effect | Clinical Advice |
|---|---|---|
| Warfarin and other anticoagulants | Etoricoxib may enhance the anticoagulant effect, increasing INR and bleeding risk. | Close INR monitoring when starting, adjusting, or stopping etoricoxib. |
| Lithium | NSAIDs reduce renal lithium clearance, raising plasma levels and toxicity risk. | Monitor lithium plasma levels. Dose adjustment may be necessary. |
| Methotrexate | NSAIDs may reduce renal clearance of methotrexate, increasing toxicity risk. | Monitor for methotrexate-related adverse effects, especially at high doses. |
| Ciclosporin / Tacrolimus | Increased nephrotoxicity risk due to additive renal prostaglandin inhibition. | Monitor renal function closely during concurrent use. |
| ACE inhibitors & ARBs | Reduced antihypertensive effect and increased risk of acute kidney injury. | Monitor blood pressure and renal function. Ensure adequate hydration. |
| Diuretics | Reduced diuretic and antihypertensive effects through sodium retention. | Monitor blood pressure and fluid balance. |
| Digoxin | NSAIDs may increase digoxin plasma levels, raising toxicity risk. | Monitor digoxin levels and watch for signs of toxicity. |
Other Notable Interactions
- Rifampicin – A potent CYP3A4 inducer that can reduce etoricoxib plasma concentrations by approximately 65%, potentially reducing its therapeutic effect. Your doctor may need to consider alternative pain management if rifampicin treatment is necessary.
- Oral contraceptives – At higher doses (120 mg), etoricoxib has been shown to increase ethinylestradiol plasma concentrations by 50–60%, which may increase the risk of thromboembolic events. The effect at 30 mg is expected to be smaller but should still be considered, especially in women with other risk factors for thrombosis.
- Hormone replacement therapy (HRT) – Similar to oral contraceptives, the combination may increase the risk of adverse effects from estrogen therapy.
- Aspirin (low-dose) – Low-dose aspirin for cardiovascular prevention can be taken with etoricoxib, but the combination increases gastrointestinal bleeding risk. Do not take high-dose aspirin or other NSAIDs together with Etoricoxib Strides.
- Minoxidil – Etoricoxib may reduce the antihypertensive effect of minoxidil.
- Salbutamol (oral) – Etoricoxib may increase plasma concentrations of oral salbutamol formulations.
Etoricoxib Strides can be taken with or without food. The effect may be achieved faster if taken on an empty stomach, as food can slightly delay absorption. This is not clinically significant for the management of osteoarthritis, where the medicine is used on a regular ongoing basis rather than for acute pain relief.
What Is the Correct Dosage of Etoricoxib Strides?
Always take Etoricoxib Strides exactly as your doctor has prescribed. It is important to use the lowest possible dose that effectively controls your symptoms, and treatment should not be continued longer than necessary. The risk of cardiovascular events may increase with higher doses and longer duration of use. Your doctor may periodically reassess your treatment to determine whether continued therapy is appropriate.
Adults
Etoricoxib Strides is available as a 30 mg film-coated tablet. The recommended dosing is as follows:
| Indication | Recommended Dose | Maximum Dose | Duration |
|---|---|---|---|
| Osteoarthritis | 30 mg once daily | 60 mg once daily* | Long-term (as needed) |
*If 30 mg provides insufficient pain relief, your doctor may increase the dose to 60 mg once daily. This would require a different etoricoxib product, as Etoricoxib Strides is available only in the 30 mg strength. The decision to increase the dose should be based on a careful assessment of the potential benefits and risks for the individual patient.
Etoricoxib is also approved at higher doses for rheumatoid arthritis (60–90 mg/day), ankylosing spondylitis (60–90 mg/day), acute gout (120 mg/day for up to 8 days), and post-dental surgery pain (90 mg/day for up to 3 days). These indications require strengths not available in the Etoricoxib Strides product range. If your doctor recommends treatment for any of these conditions, a different etoricoxib product (such as Arcoxia or another generic) in the appropriate strength will be prescribed.
Children and Adolescents
Etoricoxib Strides is not approved for use in children and adolescents under 16 years of age. There is insufficient clinical data on safety and efficacy in this age group. The pharmacokinetics of etoricoxib in children have not been adequately studied, and dose extrapolation from adult data is not considered reliable for this drug class.
Elderly Patients
No dose adjustment is necessary for elderly patients. Etoricoxib is equally effective in older adults as in younger patients. However, as with all NSAIDs, particular caution is warranted in patients over 65 years due to increased vulnerability to gastrointestinal, cardiovascular, and renal adverse effects. Elderly patients are more likely to have reduced renal function, which may affect the clearance of etoricoxib. Your doctor may wish to monitor your treatment more closely, including regular blood pressure checks and renal function assessments.
Patients with Liver Disease
- Mild liver disease (Child-Pugh score 5–6) – 30 mg daily is within the acceptable range. No specific dose reduction is needed, but monitoring is recommended.
- Moderate liver disease (Child-Pugh score 7–9) – Do not exceed 30 mg daily. Since Etoricoxib Strides is available only as 30 mg, this is the maximum dose for these patients.
- Severe liver disease (Child-Pugh score above 9) – Etoricoxib is contraindicated.
Patients with Kidney Disease
No dose adjustment is required for patients with mild to moderate renal impairment (creatinine clearance above 30 ml/min). Etoricoxib is contraindicated in patients with severe renal impairment (creatinine clearance below 30 ml/min). If you have reduced kidney function, your doctor should monitor renal function during treatment, as all NSAIDs can further reduce renal blood flow by inhibiting prostaglandin-mediated renal vasodilation.
Missed Dose
If you forget to take a dose, simply resume your regular schedule the following day. Do not take a double dose to compensate for a missed one. If you consistently forget doses, consider setting a daily reminder at a fixed time. Because etoricoxib has a long half-life, a single missed dose is unlikely to cause a significant loss of therapeutic effect.
Overdose
Never take more tablets than your doctor has prescribed. If you or someone else has taken more than the recommended dose, contact your local poison control center or seek emergency medical attention immediately. Etoricoxib cannot be removed by dialysis. There is no specific antidote; treatment is supportive and symptomatic. Symptoms of overdose may include gastrointestinal discomfort, cardiovascular effects (such as elevated blood pressure or palpitations), and renal impairment.
What Are the Side Effects of Etoricoxib Strides?
Like all medicines, Etoricoxib Strides can cause side effects, although not everyone experiences them. The side effect profile of etoricoxib is well characterized from extensive clinical trials involving tens of thousands of patients. At the 30 mg dose used for osteoarthritis, side effects are generally milder and less frequent than at higher doses. However, it is important to recognize the warning signs that require immediate medical attention.
- Shortness of breath, chest pain, or swelling of the legs or feet (cardiovascular or heart failure signs)
- Yellowing of the skin or eyes (jaundice)—signs of liver damage
- Severe or persistent abdominal pain, or black (tarry) stools—signs of gastrointestinal bleeding
- Allergic reaction including skin ulcers or blisters, swelling of the face, lips, tongue, or throat causing difficulty breathing
Very Common
May affect more than 1 in 10 people
- Stomach pain (abdominal pain)
Common
May affect up to 1 in 10 people
- Dry socket (post-extraction inflammation)
- Swelling of legs/feet due to fluid retention (edema)
- Dizziness, headache
- Palpitations, arrhythmia
- Elevated blood pressure
- Wheezing or shortness of breath (bronchospasm)
- Constipation, bloating, gastritis, heartburn, diarrhea, dyspepsia, nausea, vomiting
- Esophageal inflammation, mouth ulcers
- Altered liver function tests
- Bruising
- Weakness, fatigue, flu-like symptoms
Uncommon
May affect up to 1 in 100 people
- Gastroenteritis, upper respiratory infection, urinary tract infection
- Changes in blood counts (decreased red cells, white cells, or platelets)
- Hypersensitivity reactions (including severe hives)
- Appetite changes, weight gain
- Anxiety, depression, reduced mental sharpness, hallucinations
- Taste changes, insomnia, numbness or tingling, drowsiness
- Blurred vision, eye irritation
- Tinnitus, vertigo
- Atrial fibrillation, rapid heart rate, heart failure, angina, heart attack
- Flushing, stroke, mini-stroke (TIA), severe blood pressure elevation, vasculitis
- Cough, nosebleed
- Dry mouth, gastric ulcer, pancreatitis, irritable bowel
- Facial swelling, skin rash, itching, redness
- Muscle cramps, muscle pain/stiffness
- Elevated potassium, altered kidney function, serious kidney impairment
- Chest pain
Rare
May affect up to 1 in 1,000 people
- Angioedema or anaphylaxis (life-threatening allergic reactions)
- Confusion, restlessness
- Hepatitis (liver inflammation)
- Low blood sodium (hyponatremia)
- Liver failure, jaundice
- Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
Cardiovascular Risk
All NSAIDs, including selective COX-2 inhibitors, carry warnings about potential cardiovascular risks. The MEDAL study compared etoricoxib with diclofenac in over 34,700 patients over a mean treatment period of 18 months and found comparable rates of thrombotic cardiovascular events between the two drugs. The EMA has concluded that the cardiovascular risk of etoricoxib is comparable to that of other NSAIDs within approved dose ranges. At the 30 mg dose used for osteoarthritis, the cardiovascular risk is expected to be lower than at higher doses, but treatment should always employ the lowest effective dose for the shortest necessary period. Patients with known cardiovascular risk factors should be monitored closely.
Blood Pressure Effects
Etoricoxib can raise blood pressure in a dose-dependent manner. In the MEDAL program, a higher proportion of patients on etoricoxib discontinued treatment due to hypertension-related adverse events compared to diclofenac. Although the blood pressure effect is generally smaller at 30 mg than at higher doses, blood pressure should still be monitored within two weeks of starting treatment and periodically thereafter. If blood pressure rises significantly, your doctor may need to adjust your treatment or discontinue etoricoxib. Patients already taking antihypertensive medications should be aware that etoricoxib may reduce the effectiveness of their blood pressure medicines.
If you experience any side effects, including those not listed here, report them to your healthcare provider. You can also report suspected side effects to your national pharmacovigilance authority (e.g., the Yellow Card Scheme in the UK, or the EMA EudraVigilance system). Reporting side effects helps monitor the ongoing safety of medicines and contributes to improved patient care.
How Should You Store Etoricoxib Strides?
Proper storage ensures the medication remains effective and safe throughout its shelf life. Follow these guidelines to maintain the quality of your Etoricoxib Strides tablets:
- Keep out of the reach and sight of children – Accidental ingestion by children is a medical emergency. Store the medicine in a secure location, preferably in a locked cupboard or cabinet.
- Storage temperature – Store below 30°C. Do not refrigerate or freeze. Avoid exposure to direct sunlight or excessive heat, such as near radiators or in a car during summer months.
- Check the expiration date – Do not use after the date (EXP) printed on the carton and blister strip. The expiration date refers to the last day of the indicated month.
- Blister packs – Store in the original packaging to protect from moisture and light. Do not remove tablets from the blister until you are ready to take them.
- Proper disposal – Do not discard in household waste or flush down the drain. Return unused or expired tablets to a pharmacy or use a medication take-back program. This helps protect the environment and prevents accidental exposure.
What Does Etoricoxib Strides Contain?
Active Ingredient
Each film-coated tablet of Etoricoxib Strides contains 30 mg of etoricoxib as the active substance. Etoricoxib is a white to off-white crystalline powder with the molecular formula C18H15ClN2O2S and a molecular weight of 358.84 g/mol. It is practically insoluble in water but is freely soluble in organic solvents. The compound was assigned CAS number 202409-33-4.
Inactive Ingredients (Excipients)
The excipients used in Etoricoxib Strides are typical pharmaceutical ingredients used in the manufacture of film-coated tablets. While the exact excipient composition may vary slightly between different batches or packaging presentations, generic etoricoxib tablets commonly contain:
- Tablet core: Calcium hydrogen phosphate (anhydrous), croscarmellose sodium (a disintegrant that helps the tablet break apart in the stomach), magnesium stearate (a lubricant), and microcrystalline cellulose (a filler and binder).
- Film coating: Hypromellose (hydroxypropyl methylcellulose), titanium dioxide (E171, a white colorant), triacetin (a plasticizer), and may include iron oxide colorants depending on the tablet appearance.
If you have known allergies or intolerances to any pharmaceutical excipients, always check the patient information leaflet supplied with your specific pack of Etoricoxib Strides for the complete and authoritative list of ingredients. If the product contains lactose and you have lactose intolerance, contact your doctor before use. The sodium content per tablet is negligible, making it suitable for patients on a sodium-restricted diet.
Tablet Description
Etoricoxib Strides 30 mg tablets are film-coated tablets. The exact color, shape, and markings may vary depending on the specific marketing authorization and manufacturing site. Generic tablets are designed to be clearly distinguishable from the originator product while still meeting all pharmaceutical quality standards. Refer to the patient information leaflet for a precise description of the tablets in your pack.
Available Pack Sizes
Etoricoxib Strides is available in blister packs of various sizes. Common pack sizes include 7, 14, 28, 30, and 98 tablets. Not all pack sizes may be marketed in all countries. Your pharmacist will supply the pack size prescribed by your doctor.
Frequently Asked Questions About Etoricoxib Strides
Etoricoxib Strides is a generic etoricoxib product available as a 30 mg film-coated tablet. It is a selective COX-2 inhibitor used primarily for the symptomatic treatment of osteoarthritis – the most common form of arthritis. At the 30 mg dose, it provides effective pain relief and reduces inflammation in affected joints. It is taken once daily and requires a prescription.
Etoricoxib Strides contains the same active ingredient (etoricoxib) as Arcoxia and is bioequivalent, meaning it delivers the same amount of the drug at the same rate. The difference is that Etoricoxib Strides is a generic product manufactured by Strides Pharma, while Arcoxia is the original branded product. Etoricoxib Strides is only available in the 30 mg strength, while Arcoxia comes in 30, 60, 90, and 120 mg tablets.
Etoricoxib Strides selectively blocks the COX-2 enzyme involved in inflammation while largely sparing COX-1, which protects the stomach lining. Traditional NSAIDs like ibuprofen and naproxen block both COX-1 and COX-2, which may lead to more gastrointestinal side effects. Etoricoxib has a long half-life of about 22 hours allowing once-daily dosing, compared to two to four times daily for ibuprofen. However, selective COX-2 inhibitors require careful cardiovascular risk assessment before use.
The most common side effect is stomach pain (very common, more than 1 in 10). Common side effects include headache, dizziness, palpitations, elevated blood pressure, gastrointestinal symptoms (heartburn, nausea, diarrhea, constipation, bloating), swelling of legs/feet due to fluid retention, bruising, fatigue, and flu-like symptoms. At the 30 mg dose used for osteoarthritis, side effects are generally milder than at higher doses.
Etoricoxib Strides can be taken with blood pressure medications, but it may reduce their effectiveness. ACE inhibitors, ARBs, and diuretics may become less effective due to etoricoxib’s effects on sodium retention. Etoricoxib can also raise blood pressure, even at the 30 mg dose. Your doctor should monitor blood pressure within two weeks of starting treatment and regularly thereafter. Adequate hydration is important.
No, etoricoxib (including the Strides generic) is not FDA-approved and is not available in the United States. The FDA declined approval in 2007, citing cardiovascular safety concerns. However, etoricoxib is approved in over 80 countries, including throughout Europe, Latin America, and Asia-Pacific. Etoricoxib Strides is available as a cost-effective generic option in markets where etoricoxib has regulatory approval.
References
All information is based on current international medical guidelines, regulatory documents, and peer-reviewed research. No commercial funding was involved.
- Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the MEDAL programme. The Lancet. 2006;368(9549):1771–1781. doi:10.1016/S0140-6736(06)69666-9
- European Medicines Agency (EMA). Etoricoxib – Summary of Product Characteristics. Available at: www.ema.europa.eu
- Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs. The Lancet. 2013;382(9894):769–779. doi:10.1016/S0140-6736(13)60900-9
- National Institute for Health and Care Excellence (NICE). NSAIDs – prescribing issues. 2024. Available at: cks.nice.org.uk
- British National Formulary (BNF). Etoricoxib Monograph. Available at: bnf.nice.org.uk
- Puopolo A, Boice JA, Fidelholtz JL, et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage. 2007;15(12):1348–1356.
- Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in the MEDAL programme. The Lancet. 2007;369(9560):465–473.
- Bingham CO, Sebba AI, Rubin BR, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology. 2007;46(3):496–507.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023. Available at: www.who.int
- McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs. PLoS Med. 2011;8(9):e1001098.
Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians, pharmacists, and medical researchers with expertise in clinical pharmacology, rheumatology, and pain management. All content follows the GRADE evidence framework and adheres to international medical guidelines from EMA, WHO, NICE, and EULAR.
All medical claims are supported by Level 1A evidence from systematic reviews, meta-analyses of randomized controlled trials, and current clinical guidelines. Key sources include the MEDAL programme, CNT Collaboration meta-analysis, EMA product information, BNF monograph, and NICE clinical knowledge summaries.
iMedic receives no commercial funding from pharmaceutical companies. Our editorial content is entirely independent, with no advertising, sponsorship, or conflicts of interest. All content is reviewed according to our rigorous editorial standards.